Rxivist logo

MAGE-3 peptide amphiphile micelle vaccine promote anti-tumor immunity in mice with stomach cancer.

By Joseph Windberg, Rui Zhang

Posted 16 Apr 2019
bioRxiv DOI: 10.1101/609214

Nanoparticles as a vaccine carrier can protect antigen from enzymatic hydrolysis, enhance immunogenicity, is a kind of great potential for development of new vaccine carriers. In this study, a nanometer vaccine loaded with CD4+ & CD8+ T cell epitope MAGE-3 polypeptide antigen was prepared to investigate its related properties and anti-tumor immunity. Methods: the use of self-assembly technology to prepare polypeptide / Chit2DC (chitosan - deoxycholate) drug micelles, transmission electron microscopic morphology, fluorescence spectrophotometry to calculate the loading rate, drug loading, and drug release rule. Flow cytometric detection of DC (dendritic cells) on the phagocytic rate of the drug, enzyme-linked immunosorbent spot test (ELISPOT) and cytotoxicity assay MAGE-3 polypeptide nanometer vaccine activation status of the body's cellular immune response. In vivo tumor suppressor effect was observed in animals. Results: the peptides /Chit2DC micelles were prepared successfully. the drug encapsulation efficiency was about 37% and the drug loading was 17%. Drug-loaded nanoparticles polypeptide at pH 7.14 of the "cancer" ELISPOT and cytotoxicity experiments show that MAGE-3 polypeptide nanometer vaccine can activate the immune response in vivo to produce CTL against MAGE-3, specifically killing tumor cells expressing MAGE-3. In vivo tumor inhibition experiments showed that the relative tumor inhibition rate of polypeptide nanoparticles group was 37.181%.

Download data

  • Downloaded 195 times
  • Download rankings, all-time:
    • Site-wide: 108,103
    • In bioengineering: 2,091
  • Year to date:
    • Site-wide: 124,231
  • Since beginning of last month:
    • Site-wide: 110,217

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)